免疫学检测预测大疱性类天疱疮患者停药后复发的真实世界影响:法国多中心回顾性研究
该法国多中心回顾性研究纳入238例大疱性类天疱疮患者,评估基于免疫学检测结果决定停药对停药后3个月和6个月复发率的真实影响。结果显示,依据免疫学检测停药组、无视检测结果停药组及未检测组在3个月和6个月复发率均无显著差异。
要点
- 依据免疫学检测结果决定停药并未显著降低3个月和6个月复发率。
- 3个月复发率:依据检测组14.7%,无视检测组23.8%,未检测组13.9%(P=.5)。
- 6个月复发率:依据检测组18.9%,无视检测组28.6%,未检测组18.9%(P=.56)。
核心结论
- 在真实临床实践中,大疱性类天疱疮患者依据免疫学检测结果决定停药,与基于临床经典决策相比,并未显著降低停药后3个月和6个月的复发率。
研究设计与样本
- 法国多中心回顾性研究,纳入随访近6个月的患者238例,根据停药决定是否依据停药前3个月内进行的免疫学检测结果分为三组。
主要发现
- 停药后3个月,共36例复发:依据检测结果组95例中14例复发(14.7%),无视检测结果组21例中5例复发(23.8%),未检测组122例中17例复发(13.9%)(P=.5)。
- 停药后6个月,三组复发率分别为18.9%、28.6%和18.9%(P=.56)。
局限性
- 回顾性设计。
- 随访时间有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A high level of anti-BP180 antibodies on enzyme-linked immunosorbent assay and a persistent positive direct immunofluorescence at the end of treatment (immunologic tests, [ITs]) are predictors of relapse after treatment cessation (TC) in patients with bullous pemphigoid. OBJECTIVE: To evaluate the real-life impact of the immunologic-based decision of TC on the 3- and 6-month relapse rates after TC in bullous pemphigoid. METHODS: Retrospective multicentric study included patients followed almost 6 months after TC. Patients were classified according to whether the TC decision was in accordance with the results of ITs performed during the 3 months before TC, despite the results of ITs or without ITs performed. RESULTS: We included 238 patients. Three months after TC, 36 patients showed relapse: 14 of 95 patients with TC in accordance with IT results (14.7%); 5 of 21 with TC despite ITs (23.8%); and 17 of 122 with TC without ITs (13.9%; P = .5). Six months after TC, the relapse rate was 18.9%, 28.6%, and 18.9% (P = .56), respectively, in the 3 groups. LIMITATIONS: The retrospective design and the limited follow up. CONCLUSION: In real-life practice, in bullous pemphigoid, the 3- and 6-month relapse rates were not significantly reduced with TC decision based on results of ITs as compared with a classic clinical-based decision.
引用
- Battesti G, Garcia C, Viguier M, et al. Real-life impact of immunologic tests to predict relapse after treatment cessation in patients with bullous pemphigoid: A French multicenter retrospective study. J Am Acad Dermatol. 2022. PMID: 35091001. doi:10.1016/j.jaad.2022.01.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。